This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2004 Jan 20;109(2):143-5.

doi: 10.1161/01.CIR.0000110644.92116.91.

Endothelin expression and the progression of heart failure: exemplifying the vagaries of therapeutic development

Marvin A Konstam¹, David DeNofrio

Affiliations

Affiliation

¹ Division of Cardiology, Department of Medicine, Tufts-New England Medical Center and Tufts University School of Medicine, Boston, Mass, USA. mkonstam@tufts-nemc.org

PMID: 14734501
DOI: 10.1161/01.CIR.0000110644.92116.91

Comment

Endothelin expression and the progression of heart failure: exemplifying the vagaries of therapeutic development

Marvin A Konstam et al. Circulation. 2004.

. 2004 Jan 20;109(2):143-5.

doi: 10.1161/01.CIR.0000110644.92116.91.

Authors

Marvin A Konstam¹, David DeNofrio

Affiliation

¹ Division of Cardiology, Department of Medicine, Tufts-New England Medical Center and Tufts University School of Medicine, Boston, Mass, USA. mkonstam@tufts-nemc.org

PMID: 14734501
DOI: 10.1161/01.CIR.0000110644.92116.91

No abstract available

PubMed Disclaimer

Comment on

Endothelin A receptor antagonism in experimental congestive heart failure results in augmentation of the renin-angiotensin system and sustained sodium retention.
Schirger JA, Chen HH, Jougasaki M, Lisy O, Boerrigter G, Cataliotti A, Burnett JC Jr. Schirger JA, et al. Circulation. 2004 Jan 20;109(2):249-54. doi: 10.1161/01.CIR.0000109139.69775.EB. Epub 2003 Dec 22. Circulation. 2004. PMID: 14691038

Similar articles

Pitavastatin improves cardiac function and survival in association with suppression of the myocardial endothelin system in a rat model of hypertensive heart failure.
Saka M, Obata K, Ichihara S, Cheng XW, Kimata H, Nishizawa T, Noda A, Izawa H, Nagata K, Murohara T, Yokota M. Saka M, et al. J Cardiovasc Pharmacol. 2006 Jun;47(6):770-9. doi: 10.1097/01.fjc.0000211791.22411.0d. J Cardiovasc Pharmacol. 2006. PMID: 16810078
K(ATP) activation prevents progression of cardiac hypertrophy to failure induced by pressure overload via protecting endothelial function.
Gao S, Long CL, Wang RH, Wang H. Gao S, et al. Cardiovasc Res. 2009 Aug 1;83(3):444-56. doi: 10.1093/cvr/cvp099. Epub 2009 Mar 20. Cardiovasc Res. 2009. PMID: 19304734
Iptakalim: a new or just another KCO?
Costa AD. Costa AD. Cardiovasc Res. 2009 Aug 1;83(3):417-8. doi: 10.1093/cvr/cvp193. Epub 2009 Jun 10. Cardiovasc Res. 2009. PMID: 19515796 No abstract available.
[Heart failure and endothelins].
Sugishita Y, Miyauchi T. Sugishita Y, et al. Nihon Naika Gakkai Zasshi. 1998 Jun 10;87(6):1155-60. Nihon Naika Gakkai Zasshi. 1998. PMID: 9702032 Review. Japanese. No abstract available.
Novel imaging strategies for predicting remodeling and evolution of heart failure: targeting the Renin-Angiotensin system.
Shirani J, Narula J, Eckelman WC, Dilsizian V. Shirani J, et al. Heart Fail Clin. 2006 Apr;2(2):231-47. doi: 10.1016/j.hfc.2006.05.002. Heart Fail Clin. 2006. PMID: 17386892 Review. No abstract available.

See all similar articles

Cited by

Endothelin and the Cardiovascular System: The Long Journey and Where We Are Going.
Haryono A, Ramadhiani R, Ryanto GRT, Emoto N. Haryono A, et al. Biology (Basel). 2022 May 16;11(5):759. doi: 10.3390/biology11050759. Biology (Basel). 2022. PMID: 35625487 Free PMC article. Review.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Medical
- MedlinePlus Health Information